1. Home
  2. SDOT vs XRTX Comparison

SDOT vs XRTX Comparison

Compare SDOT & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sadot Group Inc.

SDOT

Sadot Group Inc.

BUY

Current Price

$2.06

Market Cap

4.9M

ML Signal

BUY

Logo XORTX Therapeutics Inc.

XRTX

XORTX Therapeutics Inc.

HOLD

Current Price

$0.40

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDOT
XRTX
Founded
2014
2011
Country
United States
Canada
Employees
N/A
N/A
Industry
Restaurants
Pharmaceuticals and Biotechnology
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9M
2.7M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
SDOT
XRTX
Price
$2.06
$0.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
27.0K
51.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
490.91
N/A
EPS
N/A
N/A
Revenue
$7,929,137.00
N/A
Revenue This Year
$12.76
N/A
Revenue Next Year
$5.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
60.08
N/A
52 Week Low
$0.72
$0.37
52 Week High
$13.02
$1.41

Technical Indicators

Market Signals
Indicator
SDOT
XRTX
Relative Strength Index (RSI) 42.06 39.95
Support Level $1.18 $0.37
Resistance Level $2.40 $0.60
Average True Range (ATR) 0.25 0.04
MACD 0.00 0.01
Stochastic Oscillator 58.23 21.54

Price Performance

Historical Comparison
SDOT
XRTX

About SDOT Sadot Group Inc.

Sadot Group Inc operates in the food supply chain sector, connecting producers and consumers across the globe, delivering agri-commodities from producing geographies such as the Americas, Africa, and the Black Sea to consumer markets in Southeast Asia, China and the Middle East/North Africa (MENA) region. Its reportable segment includes Sadot food service and Sadot agri-foods. The key revenue is coming from the Sadot agri-foods segment which engaged in farming, commodity trading, and shipping of food and feed.

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Share on Social Networks: